Sky Century Investment (SKYI) Interest Expenses (2024 - 2025)

Sky Century Investment (SKYI) posted quarterly Interest Expenses of $594.0 for Q3 2025, down 99.68% quarter-over-quarter from $186246.0 in Q2 2025.

Sky Century Investment (SKYI) Interest Expenses (2024 - 2025) Analysis & Trends

Sky Century Investment (SKYI) has reported Interest Expenses for 2 consecutive years, with $594.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Interest Expenses changed N/A year-over-year to $594.0; the TTM figure through May 2026 stood at $594.0 (down 99.68% YoY), while the FY2025 annual figure was $193765.0, up 14.55% from the prior year.
Interest Expenses slipped to $594.0 in Q3 2025 per SKYI's latest filing, from $186246.0 in the prior quarter.
Across five years, Interest Expenses topped out at $186246.0 in Q2 2025 and bottomed at $513.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	-
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	-400.56 Mn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	2.90 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	120.70 Mn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	2.90 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	59.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Sky Century Investment	393,547.71	393,283.71	26,045.00	-

Download Data